VPS26A expression was notably affected by clinical parameters such as the primary tumor, race (Asian), age group (41–60 and 61–80 years), tumor stage (I, II, and III), and tumor grade (II, III, and IV) (Figure 6A). Here, VPS26A is linked to neoplasm.